Status:
UNKNOWN
Population PK of Antibiotics, Sedative and Analgesics, and Antiplatelet Drugs During ECMO
Lead Sponsor:
Gachon University Gil Medical Center
Collaborating Sponsors:
Yonsei University
Conditions:
Pharmacokinetics
Extracorporeal Membrane Oxygenation
Eligibility:
All Genders
19+ years
Brief Summary
The purpose of this study is to optimize the dosage regimen of drugs in patients during during Extracorporeal Membrane Oxygenation (ECMO) by population pharmacokinetic modeling.
Eligibility Criteria
Inclusion
- Patients who are taking levofloxacin, meropenem, vancomycin, cefepime, midalzolam, dexmedetomidine, propofol, clopidogrel, ticagrelor, or prasugrel while underdoing Extracorporeal Membrane Oxygenation
Exclusion
- Pregnant women
- Receiving a therapy that can affect blood concentration due to a drug-drug interaction with levofloxacin, meropenem, vancomycin, cefepime, midalzolam, dexmedetomidine, propofol, clopidogrel, ticagrelor, or prasugrel
Key Trial Info
Start Date :
July 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 15 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05406492
Start Date
July 16 2019
End Date
July 15 2024
Last Update
June 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gacheon University Gil Medical Center
Incheon, South Korea, 21565